PRESS RELEASE published on 12/23/2024 at 21:04, 1 year 9 months ago Informations privilégiées / Autres communiqués TME Pharma réussit son offre publique de 2,6 millions d'euros, renforçant sa position financière jusqu'en juin 2025. Les actionnaires soutiennent la levée de fonds pour NOX-A12 et NOX-E36 Augmentation De Capital Offre Publique TME Pharma NOX-A12 NOX-E36
BRIEF published on 12/04/2024 at 19:55, 1 year 9 months ago TME Pharma annonce une mise à jour stratégique et un plan de financement de 2,6 millions d'euros Stratégie D'entreprise Offre Publique Plan De Financement Développement Du NOX-A12 Priorité Aux Actionnaires
BRIEF published on 12/04/2024 at 19:55, 1 year 9 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 9 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une nouvelle stratégie et un financement garanti de 2,6 millions d'euros pour ses projets NOX-A12 et NOX-E36 jusqu'en juin 2025 Financement Offre Publique TME Pharma NOX-A12 NOX-E36
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 9 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 10 months ago TME Pharma présente ses résultats sur NOX-A12 dans le glioblastome Thérapie Contre Le Cancer Glioblastome NOX-A12 Inhibition Du Point De Contrôle Immunitaire Microenvironnement Tumoral
BRIEF published on 11/23/2024 at 10:59, 1 year 10 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 10 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la présentation d'un poster par le National Cancer Institute américain sur l'inhibition de CXCL12 par NOX-A12 dans le glioblastome à la réunion annuelle du SNO 2024 Glioblastome TME Pharma NOX-A12 National Cancer Institute Inhibition
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 10 months ago Inside Information / Other news releases TME Pharma presents poster on NOX-A12 inhibition of CXCL12 in glioblastoma at 2024 SNO Annual Meeting, demonstrating enhanced anti-tumor immune responses in brain cancer models Glioblastoma TME Pharma NOX-A12 CXCL12 Inhibition SNO Annual Meeting
BRIEF published on 08/12/2024 at 19:05, 2 years 1 month ago TME Pharma augmente les ressources allouées au contrat de liquidité Contrat De Liquidité Répartition Des Actions Décision De L'AMF TME Pharma Investir Dans Des Titres
Published on 09/30/2026 at 15:50, 1 hour 14 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 09/30/2026 at 14:37, 2 hours 27 minutes ago NuRAN Leverages Starlink Backhaul to Drive Higher Revenue Per Rural Site
Published on 09/30/2026 at 14:31, 2 hours 33 minutes ago First Breach Expands Ammunition Manufacturing Operations to Seven Days a Week
Published on 09/30/2026 at 14:07, 2 hours 57 minutes ago Worksport COR Energy System Now Available Through Amazon
Published on 09/30/2026 at 13:30, 3 hours 34 minutes ago Nextech3D.ai Engages MZ Group to Lead Strategic Investor Relations Program
Published on 09/30/2026 at 16:32, 31 minutes ago VVV Sports Limited: Interim Results for the six months ended 30 June 2026
Published on 09/30/2026 at 16:30, 34 minutes ago Original-Research: HORNBACH Holding AG & Co. KGaA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 09/30/2026 at 16:20, 44 minutes ago EQS-Adhoc: MS Industrie AG: MS XTEC acquires a 51% majority stake in IDAS d.o.o., Mol, Serbia
Published on 09/30/2026 at 16:00, 1 hour 4 minutes ago Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Published on 09/30/2026 at 15:41, 1 hour 23 minutes ago Branicks Group AG 2026 Half-Year Report: Steady Operational Progress, Key Structural Changes Implemented
Published on 09/30/2026 at 12:14, 4 hours 50 minutes ago Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/30/2026 at 12:00, 5 hours 4 minutes ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 09/30/2026 at 12:00, 5 hours 4 minutes ago Capital increase through exercise of subscription rights
Published on 09/30/2026 at 08:45, 8 hours 19 minutes ago Air Liquide invests over 170 million euros to support a semiconductor leader expanding manufacturing capabilities in Japan
Published on 09/30/2026 at 08:45, 8 hours 19 minutes ago Air Liquide investit plus de 170 millions d’euros pour accompagner un leader des semi-conducteurs dans le développement de ses capacités de production au Japon
